HTG EdgeSeq PATH Assay
HTG Molecular Diagnostics plans to launch the HTG EdgeSeq PATH Assay for research use only by the end of the second quarter. The assay has been designed for retrospective gene expression profiling to complement traditional immunohistochemistry (IHC) testing. The test assesses mRNA expression of large numbers of biomarkers when formalin-fixed, paraffin-embedded sample availability is limited, the company said. It is designed to detect up to 470 mRNA targets, typically assessed by IHC.
Bio-Rad Bio-Plex Pro Human Apolipoprotein Panel
Bio-Rad Laboratories has launched the Bio-Plex Pro Human Apolipoprotein Panel. The 10-plex panel is an expansion of the company's multiplex immunoassay offerings that allows researchers to rapidly detect and quantify key human apolipoproteins associated with cardiovascular disease. The panel includes the largest number of apolipoproteins on the market and includes four targets — Apo C1, Apo D, Apo J, and Apo H — not found on other multiplex panels. It includes high sample detectability, premixed and ready-to-use reagents, and streamlined data analysis, the company said. The panel is for research use only and is compatible with Bio-Plex 200, Bio-Plex 3D, Bio-Plex MAGPIX, and all Luminex platforms.
LabCorp VistaSeq Hereditary Cancer Panel
Laboratory Corporation of America has launched 10 new panels to test for risk of specific hereditary cancer syndromes. The number of cancer genes that can be assessed has been increased to 59. The VistaSeq Hereditary Cancer Panel assesses genetic mutations associated with common hereditary cancers, such as breast, ovarian, melanoma, pancreatic, colorectal, endometrial, gastric, and prostate cancers.
For more new products and services, please visit the New Products page on our website.